Part D Catastrophic Coverage: Manufacturers Could Agree To Increased ‘Liability’
But drug makers want their financial contribution to go toward reducing beneficiary costs, not to replace plans’ insurance risk, according to comments submitted to two House committees on draft legislation.
You may also be interested in...
Price inflation rebates are expected to generate $50bn in savings over 10 years, according to the Congressional Budget Office.
Biopharma manufacturers might not like the cost offsets that would cover the out-of-pocket maximum for patients in Medicare's drug program; committees seek comment on range of issues.
As further details emerge, questions continue about whether the CMMI model could delay access to Lyfgenia and Casgevy; states will be added on ‘rolling basis.’ A new administration could change or cancel the model, but a CMS official predicts that is unlikely.